### Comment:
This drug will never be a standard of care. It is going to be a last resort drug for a very specific subset of inpatients.

### REPLY:
but we knew that.  i figured for a company with such a small market cap and not many drugs in the pipeline that this would make a big difference to their valuation.

### END.